Last reviewed · How we verify
Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy (TREAZURE)
This is a multicenter, open-label, prospective, phase 2 study of trastuzumab, bevacizumab, and paclitaxel as second-line treatment for patients with HER2-positive advanced gastric cancer who had progressed on first-line chemotherapy including trastuzumab or anti-HER2 agents.
Details
| Lead sponsor | Kangbuk Samsung Hospital |
|---|---|
| Phase | PHASE1, PHASE2 |
| Status | RECRUITING |
| Enrolment | 47 |
| Start date | Sun Jan 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Dec 31 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- HER2-positive Advanced Gastric Cancer
Interventions
- trastuzumab, bevacizumab with paclitaxel (triple combination)
Countries
South Korea